Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 11—November 2016
Dispatch

Novel Levofloxacin-Resistant Multidrug-Resistant Streptococcus pneumoniae Serotype 11A Isolates, South Korea

Miey Park, Hyun Soo Kim, Han-Sung Kim, Ji Young Park, Wonkeun Song, Hyoun Chan Cho, and Jae-Seok KimComments to Author 
Author affiliations: Hallym University College of Medicine, Seoul, South Korea

Main Article

Table 2

Antimicrobial susceptibilities of 16 levofloxacin-resistant Streptococcus pneumoniae clinical isolates identified from patients at a hospital in South Korea, 2009–2014*

Strain
MIC, μg/mL (resistance)
LEV
OFL
CIP†
PEN
AMX
CRO
MER
ERY
CLI
VAN
LZD
TET
TIG†
HM-646 16 (R) 32 (R) 32 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-669 16 (R) 32 (R) 32 >16 (R) >16 (R) >16 (R) 8 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-683 8 (R) 16 (R) 16 4 (I) 2 (S) 2 (I) 1 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-688 16 (R) 32 (R) 32 >16 (R) >16 (R) >16 (R) 8 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-730 8 (R) 16 (R) 8 4 (I) 2 (S) 2 (I) 0.5 (I) >16 (R) >16 (R) 0.5 (S) 0.5 (S) >16 (R) 0.03
HM-762 32 (R) 64 (R) 32 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 0.5 (S) >16 (R) 0.015
HM-781 16 (R) 32 (R) 16 16 (R) 16 (R) >16 (R) 8 (R) >16 (R) >16 (R) 0.5 (S) 0.5 (S) 16 (R) 0.03
HM-787 16 (R) 32 (R) 64 16 (R) 16 (R) >16 (R) 8 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-809 16 (R) 32 (R) 64 16 (R) >16 (R) >16 (R) 4 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-854 8 (R) 16 (R) 16 0.06 (S) 0.06 (S) 0.5 (S) <0.015 (S) 8 (R) 0.06 (S) 0.5 (S) 1 (S) >16 (R) 0.03
HM-878 16 (R) 32 (R) 32 16 (R) >16 (R) >16 (R) 8 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) 4 (R) 0.03
HM-953 16 (R) 32 (R) 64 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-970 32 (R) 64 (R) 32 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-1017 64 (R) 128 (R) 64 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03
HM-1050 32 (R) 64 (R) 64 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) 0.5 (S) 0.03
HM-1055 16 (R) 32 (R) 128 >16 (R) >16 (R) >16 (R) 16 (R) >16 (R) >16 (R) 0.5 (S) 1 (S) >16 (R) 0.03

*AMX, amoxicillin; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; I, intermediate; LEV, levofloxacin; LZD, linezolid; MER, meropenem; OFL, ofloxacin; PEN, penicillin; R, resistant; S, susceptible; TET, tetracycline; TIG, tigecycline; VAN, vancomycin.
†No susceptibility breakpoints are established for ciprofloxacin and tigecycline.

Main Article

Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external